Benzinga | Jun 23, 2021 08:01AM EDT

GT Biopharma Highlights Presentation Of Interim GTB-3550 Trike Monotherapy Clinical Trial Results At 2021 Raymond James Human Health Innovation Conference

GT Biopharma, Inc. (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary NK cell engager (TriKE(tm)) protein biologic technology platform, announced Jeffrey S. Miller, M.D., Deputy Director of the Masonic Cancer Center and Consulting Chief Scientific Officer, provided an update concerning GTB-3550 TriKE(tm) monotherapy clinical trial interim results at the 2021 Raymond James Health Innovation Conference. The presentation will be available on the "News & Media" page of the GT Biopharma website at www.gtbiopharma.com/news-media/presentation.